CRTE7A2 TCR-fusion protein therapy (Corregene)

N/A

Report date: 2022/08/26 14:58:50

Base Information

Drug NameCRTE7A2 TCR-fusion protein therapy (Corregene)
Drug Alias NameHPV16 E6/E7 TCR-fusion protein therapy (Corregene)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProtein E7 modulatorsProtein E6 modulators
TargetsProtein E7Protein E6
Therapy Area/IndicationsUterine Cervical NeoplasmsCervical Intraepithelial NeoplasiaPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCorregene Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCorregene Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsCervical Intraepithelial NeoplasiaPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A